| 趋化因子CCL21的研究进展 |
| |
| 引用本文： | 宫婷.趋化因子CCL21的研究进展[J].国际肿瘤学杂志,2008,35(10):744-747. |
| |
| 作者姓名： | 宫婷 |
| |
| 作者单位： | 天津市肿瘤医院消化肿瘤内科,300060 |
| |
| 摘 要： | 趋化因子CCL21属于CC类趋化因子,主要表达于周围淋巴组织.研究表明,CCL21可以促使血管内皮细胞黏附流动的T细胞参与淋巴细胞归巢,能够很强地趋化T、B淋巴细胞、成熟树突状细胞(DC)及NK细胞,参与T细胞免疫应答.CCL21可以募集活化效应细胞,使其肿瘤周围聚集,在肿瘤治疗方面具有较大潜力.CCL21的高表达也与许多免疫疾病的发生相关.
|
| 关 键 词： | 趋化因子 CC 肿瘤 自身免疫 |
Research advances of chemokine CCL21 |
| |
| GONG Ting.Research advances of chemokine CCL21[J].Journal of International Oncology,2008,35(10):744-747. |
| |
| Authors: | GONG Ting |
| |
| Abstract: | CCL21 is originally reported as a CC chemokine mainly expressed in secondary lymphoid tissues. CCL21 can dictate lymphocytes homing in the flow environment,where T cells use integrins stimulated by CCL21 to arrest on endothelial cells,and can act as a chemoattractant for T cells,B cells,mature dentritic cells and natural killer cells strongly. CCL21 can collect activated effector cells and keep them around the tumor. It is also a pivotal molecule for priming T cell responses. Therefore,CCL21 plays a potential role in anti-tumor therapy, and its high expression is responsible for many immune diseases. |
| |
| Keywords: | Chemokines CC Neoplasms Autoimmunity |
| 本文献已被 万方数据 等数据库收录！ |
|
